Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)

• Company Description    Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. Number of Employees: 420

• Price / Volume Information    Yesterday's Closing Price: $6.66 Daily Weekly Monthly 20 Day Moving Average: 69,393 shares Shares Outstanding: 57.51 (millions) Market Capitalization: $382.98 (millions) Beta: 0.81 52 Week High: $9.16 52 Week Low: $5.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.06% -4.62% 12 Week -9.39% -13.15% Year To Date 9.36% -4.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HOLTZMAN ST. SCIENCE PARK - REHOVOT,L3 7670402 ISR ph: 972-8940-6472 fax: 972-8940-6473 ir@kamada.com http://www.kamada.com

• General Corporate Information    Officers Amir London - Chief Executive Officer Lilach Asher-Topilsky - Chair of the Board of Directors Eran Nir - Chief Operating Officer Chaime Orlev - Chief Financial Officer Uri Botzer - Director Peer Information Kamada Ltd. (CORR.) Kamada Ltd. (RSPI) Kamada Ltd. (CGXP) Kamada Ltd. (BGEN) Kamada Ltd. (GTBP) Kamada Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M6240T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/10/25 Share - Related Items Shares Outstanding: 57.51 Most Recent Split Date: (:1) Beta: 0.81 Market Capitalization: $382.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.39 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 25.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/10/25

• Fundamental Ratios P/E Current FY Estimate: 16.93 Trailing 12 Months: 19.59 PEG Ratio: 0.68 Price Ratios Price/Book: 1.47 Price/Cash Flow: 13.55 Price / Sales: 2.26 EPS Growth vs. Year Ago Period: 62.50% vs. Previous Quarter: 85.71% Sales Growth vs. Year Ago Period: 5.37% vs. Previous Quarter: 1.67% ROE 09/30/25 - - 06/30/25 - 7.41 03/31/25 - 6.31 ROA 09/30/25 - - 06/30/25 - 5.18 03/31/25 - 4.43 Current Ratio 09/30/25 - - 06/30/25 - 4.00 03/31/25 - 3.30 Quick Ratio 09/30/25 - - 06/30/25 - 2.21 03/31/25 - 1.93 Operating Margin 09/30/25 - - 06/30/25 - 11.22 03/31/25 - 9.60 Net Margin 09/30/25 - - 06/30/25 - 11.22 03/31/25 - 9.60 Pre-Tax Margin 09/30/25 - - 06/30/25 - 11.07 03/31/25 - 10.47 Book Value 09/30/25 - - 06/30/25 - 4.52 03/31/25 - 4.38 Inventory Turnover 09/30/25 - - 06/30/25 - 1.23 03/31/25 - 1.21 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©